MAIA Biotechnology, Inc. (MAIA)
ASE · Healthcare · Biotechnology
$1.30
+0.00%
Closing price as of 2026-06-12 · Source: TEK2day Finance
Key Metrics
Market Cap
$79.0M
Shares Outstanding
60.8M
Exchange
ASE
Currency
USD
About MAIA Biotechnology, Inc.
MAIA Biotechnology, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the development of targeted immunotherapies for cancer. Its lead product Ateganosine, a telomere-targeting agent currently in clinical development to evaluate its activity in Non-Small Cell Lung Cancer (NSCLC). The company was incorporated in 2018 and is headquartered in Chicago, Illinois.